Modality
siRNA
MOA
STINGag
Target
IL-17A
Pathway
Lipid Met
SLE
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Dec 2027
Phase 3Current
NCT07785913
1,717 pts·SLE
2017-10→2026-02·Terminated
NCT07267960
1,681 pts·SLE
2018-02→2027-12·Completed
3,398 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-082mo agoPh3 Readout· SLE
2027-12-171.7y awayPh3 Readout· SLE
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2026-02-08 · 2mo ago
SLE
Ph3 Readout
2027-12-17 · 1.7y away
SLE
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07785913 | Phase 3 | SLE | Terminated | 1717 | EDSS |
| NCT07267960 | Phase 3 | SLE | Completed | 1681 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |